ReviewBMC urology2016
Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases.
Review in BMC urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 41 citations in OpenAlex.
- Storage-dependent changes in the soluble urinary proteome: a pre-analytical stability study in inflammatory clinical urine samples.The journal of liquid biopsy · 2026Article
- Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.Genes & genomics · 2025Review
- Recent progress in mass spectrometry-based urinary proteomics.Clinical proteomics · 2024Review
- Unveiling the Dichotomy of Urinary Proteins: Diagnostic Insights into Breast and Prostate Cancer and Their Roles.Proteomes · 2023Review
- Peptidomics analysis reveals changes in small urinary peptides in patients with interstitial cystitis/bladder pain syndrome.Scientific reports · 2022Article
- Alterations in the molecular composition of COVID-19 patient urine, detected using Raman spectroscopic/computational analysis.PloS one · 2022Article
- Article
- Metabolomic and lipidomic approaches to identify biomarkers for bladder cancer and interstitial cystitis (Review).Molecular medicine reports · 2020Review
- Urinary Biomarkers: Diagnostic Tools for Monitoring Athletes' Health Status.International journal of environmental research and public health · 2020Article
- Biomarker discovery and beyond for diagnosis of bladder diseases.Bladder (San Francisco, Calif.) · 2020Article
- Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics.BioMed research international · 2020Article
- Urine Nuclear Magnetic Resonance (NMR) Metabolomics in Age-Related Macular Degeneration.Journal of proteome research · 2019Article
- Unmasking molecular profiles of bladder cancer.Investigative and clinical urology · 2018Review
- Urine: Waste product or biologically active tissue?Neurourology and urodynamics · 2018Article
- Effect of Sweetened Dried Cranberry Consumption on Urinary Proteome and Fecal Microbiome in Healthy Human Subjects.Omics : a journal of integrative biology · 2018Article
- Serial-omics characterization of equine urine.PloS one · 2017Article
- Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2017Article
- Three-Dimensionally Functionalized Reverse Phase Glycoprotein Array for Cancer Biomarker Discovery and Validation.Journal of the American Chemical Society · 2016Article
- Translational Research for Pediatric Lower Urinary Tract Dysfunction.International neurourology journal · 2016Review
- Apolipoprotein A1 as a novel urinary biomarker for diagnosis of bladder cancer: A systematic review and meta-analysis.Indian journal of urology : IJU : journal of the Urological Society of IndiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAssays of molecular biomarkers in urine are non-invasive compared to other body fluids and can be easily repeated. Based on the hypothesis that the secreted markers from the diseased organs may locally release into the body fluid in the vicinity of the injury, urine-based assays have been considered beneficial to monitoring bladder health and urological diseases. The urine proteome is much less complex than the serum and tissues, but nevertheless can contain biomarkers for diagnosis and prognosis of diseases. The urine metabolome has a much higher number and concentration of low-molecular metabolites than the serum or tissues, with a far lower lipid concentration, yet informs directly about dietary and microbial metabolism. DISCUSSION: We here discuss the use of mass spectrometry-based proteomics and metabolomics for urine biomarker assays, specifically with respect to the underlying mechanisms that trigger the pathological condition.
conclusionMolecular biomarker profiles, based on proteomics and metabolomics studies, reliably distinguish patients from healthy controls, stratify sub-populations with respect to treatment options, and predict therapeutic response of patients with urological disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.